Skip to main content

Table 1 All examined cases of iCJD from countries of treatment with clinical, molecular and histopathological features

From: Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study

Case number

Iatrogenic exposure

Country

Sex

Age at death (years)

Disease duration (months)

Mean incubation perioda (years)

Codon 129 genotype

PrPSc type

Histopath. phenotype

Two or more histological sections

1 b,c

DML

United States

M

26

5

19

na

na

MM(MV)1

yes

2d,e

DMT

 

F

39

4

6

MM

1

MM(MV)1

yes

3

GH

 

M

33

6

23

VV

na

VV2

yes

4

GH

 

M

39

17

24

MV

na

MV2K

yes

5

GH

 

M

39

7

27

MM

2

Atypical

yes

6e

GH

 

F

41

2

26

MM

1

MM(MV)1

yes

7

GH

 

M

43

26

23

MV

i+2

MV2K

yes

8

GH

 

M

44

18

32.5

MV

i+2

MV2K

yes

9 e

GH

 

M

51

14

38

MM

i

MMi

yes

10 e

GH

 

M

54

2

41.5

MM

1

MM(MV)1

yes

11

GH

 

M

23

19

10

na

na

MV2K or MMi

no

12

GH

 

M

34

18

23

na

na

MV2K or MMi

no

13

GH

 

M

37

3

21

na

na

MM(MV)1

no

14

GH

 

M

42

5

>28f

MM

na

Undeterminedg

no

15h

GH

 

M

52

4

43

na

na

MM(MV)1

no

mean±SDi

   

41±8.5

11±8

28±9.5j

    

16

DML

Australia

M

32

3.5

16.5

MV

na

MM(MV)1

yes

17 k

DML

 

M

62

2

5

na

na

MM(MV)1

yes

mean±SD

   

47±21

3±1

11±8

    

18

DML

France

M

25

8

8

MV

na

MM(MV)1

yes

19

DMUnk

 

M

29

6

25

MV

1

MM(MV)1

yes

20

DML

 

M

42

5

6

VV

na

VV2

yes

21

DML

 

F

50

14

11

MM

na

MMi

yes

22

DML

 

F

62

4

4

VV

na

VV2

yes

23

DML

 

F

71

4

4

MV

na

MV2K

yes

mean±SD

   

46.5±18

7±4

10±8

    

24

DML

Italy

F

23

27

21

VV

2

VV2

yes

25

DML

 

F

26

6

12

MM

na

MM(MV)1

no

26

DML

 

M

42

3.5

18

MM

1+2

MM1+2

yes

27

DML

 

M

75

3

18

VV

2

VV2

yes

mean±SD

   

41.5±24

10±11.5

17±4

    
  1. aThe mean incubation period was measured from the mid-point of GH therapy or date of receipt of the dura graft to the clinical onset of the disease; b[3]; cNumbers in bold indicate iCJD cases with Aβ-positive pathology; d[32]; e [10]; fUnknown starting date for GH treatment (incubation period thought to be greater than 28 years); gAssociated with severe spongiosis and gliosis; hBiopsy; iMean±SD of the US iCJD cases does not include DML (case 1) and DMT (case 2); jIt does not include case 14; k[58]; Histopath. histopathological, DMUnk dura mater of an unknown (Unk) brand, na not available SD standard deviation